ClinicalTrials.gg
RecruitingNCT07473206VISION-HYSTUpdated Mar 16, 2026

Environmental Visual Distraction With Nitrous Oxide During Outpatient Hysteroscopy: A Randomized Pilot Study

An interventional study of Environmental Visual Distraction (Virtual Window) and The control group receives nitrous oxide (N₂O) analgesia, which is a drug intervention, even though it is part of routine clinical practice. in Pain During Outpatient Hysteroscopy, sponsored by Ospedale degli Infermi di Biella. Recruiting at 1 site in Italy. Open to female participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Ospedale degli Infermi di Biella · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Pain with a site in Italy — 35 open to participants now, 41 under way, 1 of them phase 3. Pain · Italy.

Planned enrollment
109th of 156
50 · median 80
Started
2026
with 7 others
No phase
102 of 213
14 open now
Primary completion
2026-09
later than 22 of 40 live
Registered
200th of 213
by date

Among the 213 studies in Pain with a site in Italy, this one is the 109th largest by planned enrollment of the 156 interventional ones that give a count, is one of 8 that started in 2026, is one of 102 with no phase, reaches primary completion later than 22 of the 40 other live ones, and was the 200th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

35 of the 213 studies in Pain with a site in Italy are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 25 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Pain with a site in Italy, or all of them as a file.
02

Study summary

This document describes the protocol of a pilot randomized clinical study evaluating the effect of environmental visual distraction combined with nitrous oxide (N₂O) analgesia on the procedural experience of patients undergoing outpatient operative hysteroscopy at the Hysteroscopy Unit of ASL Biella.

Office hysteroscopy is widely used for the diagnosis and treatment of intrauterine conditions such as abnormal uterine bleeding, infertility, and endocavitary pathology. Thanks to technological advances and the miniaturization of instruments, many procedures can now be performed in an outpatient setting without general anesthesia. However, pain perception and procedural anxiety may limit patient tolerance and the completion of the examination.

Nitrous oxide is commonly used for analgesia in outpatient hysteroscopy due to its rapid onset, reversibility, and favorable safety profile. It allows effective pain control without deep sedation and enables quick patient recovery after the procedure.

In addition to pharmacological approaches, environmental strategies aimed at reducing anxiety and discomfort are increasingly studied. In this protocol, a virtual environmental window-a wall-mounted screen displaying relaxing videos such as natural landscapes or marine scenes-is used as a visual distraction tool to potentially improve the patient's procedural experience.

The primary objective is to evaluate the effect of the environmental setting on the patient's experience during hysteroscopy, measured using the Visual Analogue Scale (VAS) for pain after the procedure. The secondary outcome is the rate of referral to the operating room following outpatient hysteroscopy. Results will also be stratified by parity and hysteroscopic instrument used.

The study will enroll 50 patients aged 25-60 years who are eligible for outpatient hysteroscopy and nitrous oxide analgesia. Participants will be randomized into two groups using sealed envelopes. The intervention group will receive nitrous oxide combined with visual environmental distraction, while the control group will receive nitrous oxide alone according to routine clinical practice.

After the procedure, patients will complete the VAS pain scale (0-10) to assess the pain experienced during the intervention. Clinical and procedural data will be collected and analyzed using descriptive and exploratory statistical methods. Outcome assessors will be blinded to group allocation.

The study follows international ethical standards, including the Declaration of Helsinki, Good Clinical Practice guidelines, and European data protection regulations (GDPR). Nitrous oxide is part of routine care and is not the experimental component of the study.

Overall, this pilot study aims to explore whether a simple non-pharmacological environmental intervention can reduce perceived pain and improve patient tolerance during outpatient hysteroscopy, providing preliminary data for future larger studies.

03

Conditions studied

  • Pain During Outpatient Hysteroscopy

Browse trials for

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 25 to 60 years

Candidates for outpatient hysteroscopy

Clinically eligible for nitrous oxide (N₂O) analgesia according to routine clinical practice

Able to understand and sign

Exclusion criteria

Exclusion Criteria:

  • to nitrous oxide (N₂O), including:

Known or suspected pneumothorax

Severe obstructive pulmonary disease

Confusional state or altered consciousness

Confirmed or suspected pregnancy

Previous major cervical surgery (e.g., conization)

Refusal or withdrawal of

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Intervention

    A wall-mounted screen displaying relaxing visual content (e.g., natural landscapes, ocean scenes, or aquarium environments) is activated during outpatient hysteroscopy to provide environmental visual distraction. The visual stimulus begins approximately 5 minutes before the procedure and continues throughout the intervention. This non-pharmacological environmental support is used in addition to standard analgesia with nitrous oxide (N₂O) to potentially reduce perceived pain and improve patient comfort during the procedure.

    Procedure: Environmental Visual Distraction (Virtual Window)

  • Placebo comparator
    Control

    Patients receive nitrous oxide (N₂O) analgesia alone according to routine clinical practice during outpatient hysteroscopy.

    Drug: The control group receives nitrous oxide (N₂O) analgesia, which is a drug intervention, even though it is part of routine clinical practice.

Interventions

  • ProcedureEnvironmental Visual Distraction (Virtual Window)

    A wall-mounted screen displaying relaxing visual content (e.g., natural landscapes, ocean scenes, or aquarium environments) is activated during outpatient hysteroscopy to provide environmental visual distraction. The visual stimulus begins approximately 5 minutes before the procedure and continues throughout the intervention. This non-pharmacological environmental support is used in addition to standard analgesia with nitrous oxide (N₂O) to potentially reduce perceived pain and improve patient comfort during the procedure.

  • DrugThe control group receives nitrous oxide (N₂O) analgesia, which is a drug intervention, even though it is part of routine clinical practice.

    Patients receive inhaled nitrous oxide (N₂O) administered through a buccal-nasal mask starting approximately 5 minutes before the outpatient hysteroscopy procedure and continuing throughout the intervention. Nitrous oxide is used as routine analgesia according to standard clinical practice to reduce pain and anxiety during the procedure. No environmental visual distraction or additional experimental intervention is applied in this group.

06

What researchers measure

Primary outcomes

  1. Pain intensity during outpatient hysteroscopy measured by Visual Analogue Scale (VAS)

    Pain perceived during the hysteroscopy procedure measured using the Visual Analogue Scale (VAS) from 0 (no pain) to 10 (worst imaginable pain), assessed immediately after the procedure.

    Time frame: Immediately after completion of the hysteroscopy procedure (within 5 minutes).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 5 months is below that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 16, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07473206
Lead sponsor
Ospedale degli Infermi di Biella
Responsible party
Bianca Masturzo (MD, Ospedale degli Infermi di Biella) — Principal investigator
First posted
Mar 16, 2026
Start date
Mar 9, 2026
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Alessandro Messina, MD
Contact
alessandro.messina@aslbi.piemonte.it
01515157001

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion